Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of PXVX0317 (CHIKV-VLP) in Healthy Adults
NCT03483961Phase 2Completed
- Sponsor
- Bavarian Nordic
- Start
- Apr 2018
- Primary completion
- Sep 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CHIKV VLP vaccine in chikungunya virus infection, sponsored by Bavarian Nordic. Started Apr 2018; status: completed.
02
Drugs
CHIKV VLP vaccine
03
Conditions
chikungunya virus infection
Beyond the preview
Go deeper on NCT03483961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03483961.